Medpace Holdings, Inc. vs UL Solutions Inc., two Biotechnology stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where MEDP and ULS diverge most: on debt / equity, MEDP reads 0.00 and ULS reads 0.27; on revenue growth, MEDP reads +24.1% and ULS reads +6.9%. The rest of the comparable metrics sit closer together. What MEDP's price implies is a somewhat stretched bet versus history (whole-company basis). What ULS's price implies is a somewhat stretched bet versus history (segment-resolved basis). The bull and bear cases for each are in their full reports below.
| Metric | MEDP | ULS |
|---|---|---|
| Price | $538.16 | $87.26 |
| Market cap | $15.6B | $17.8B |
| Sector | Biotechnology | Biotechnology |
| Stage | Growth | Mature |
| Implied growth (priced in) | +34.1% | — |
| P/E | 33.9 | 50.7 |
| P/B | 26.05 | 13.32 |
| P/S | 5.82 | 5.73 |
| EV/EBITDA | 25.3 | 29.9 |
| Revenue growth | +24.1% | +6.9% |
| Operating margin | 20.0% | 18.2% |
| Net margin | 17.2% | 11.3% |
| Return on equity | 77.0% | 26.2% |
| Return on assets | 21.6% | 11.8% |
| Return on invested capital | 79.0% | 24.5% |
| FCF yield | 4.6% | 2.5% |
| Dividend yield | — | 0.6% |
| Debt / equity | 0.00 | 0.27 |
| Current ratio | 0.85 | 1.16 |
| Altman Z (solvency) | 7.14 | 7.52 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.